Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/LDLRAD4_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/LDLRAD4_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/LDLRAD4_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/LDLRAD4_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/LDLRAD4_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/LDLRAD4_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/LDLRAD4_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:20001466 | Oral cavity | EOLP | negative regulation of cell motility | 65/2218 | 359/18723 | 3.09e-04 | 2.89e-03 | 65 |
GO:000717816 | Oral cavity | EOLP | transmembrane receptor protein serine/threonine kinase signaling pathway | 64/2218 | 355/18723 | 3.85e-04 | 3.46e-03 | 64 |
GO:001701514 | Oral cavity | EOLP | regulation of transforming growth factor beta receptor signaling pathway | 29/2218 | 128/18723 | 4.03e-04 | 3.58e-03 | 29 |
GO:00400136 | Oral cavity | EOLP | negative regulation of locomotion | 67/2218 | 391/18723 | 1.17e-03 | 8.47e-03 | 67 |
GO:000718311 | Oral cavity | EOLP | SMAD protein complex assembly | 6/2218 | 13/18723 | 2.24e-03 | 1.39e-02 | 6 |
GO:00900924 | Oral cavity | EOLP | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 46/2218 | 256/18723 | 2.53e-03 | 1.53e-02 | 46 |
GO:00901012 | Oral cavity | EOLP | negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 27/2218 | 131/18723 | 2.76e-03 | 1.65e-02 | 27 |
GO:00305123 | Oral cavity | EOLP | negative regulation of transforming growth factor beta receptor signaling pathway | 18/2218 | 81/18723 | 5.86e-03 | 2.96e-02 | 18 |
GO:001071711 | Oral cavity | EOLP | regulation of epithelial to mesenchymal transition | 20/2218 | 99/18723 | 1.14e-02 | 4.99e-02 | 20 |
GO:004325432 | Oral cavity | NEOLP | regulation of protein-containing complex assembly | 95/2005 | 428/18723 | 2.76e-12 | 5.29e-10 | 95 |
GO:004593633 | Oral cavity | NEOLP | negative regulation of phosphate metabolic process | 88/2005 | 441/18723 | 5.20e-09 | 2.87e-07 | 88 |
GO:001056333 | Oral cavity | NEOLP | negative regulation of phosphorus metabolic process | 88/2005 | 442/18723 | 5.82e-09 | 3.15e-07 | 88 |
GO:004232633 | Oral cavity | NEOLP | negative regulation of phosphorylation | 79/2005 | 385/18723 | 8.76e-09 | 4.48e-07 | 79 |
GO:007155924 | Oral cavity | NEOLP | response to transforming growth factor beta | 59/2005 | 256/18723 | 8.84e-09 | 4.49e-07 | 59 |
GO:007156024 | Oral cavity | NEOLP | cellular response to transforming growth factor beta stimulus | 58/2005 | 250/18723 | 9.13e-09 | 4.56e-07 | 58 |
GO:000717923 | Oral cavity | NEOLP | transforming growth factor beta receptor signaling pathway | 48/2005 | 198/18723 | 4.01e-08 | 1.66e-06 | 48 |
GO:000193332 | Oral cavity | NEOLP | negative regulation of protein phosphorylation | 70/2005 | 342/18723 | 6.77e-08 | 2.61e-06 | 70 |
GO:000717822 | Oral cavity | NEOLP | transmembrane receptor protein serine/threonine kinase signaling pathway | 70/2005 | 355/18723 | 3.04e-07 | 9.62e-06 | 70 |
GO:005127115 | Oral cavity | NEOLP | negative regulation of cellular component movement | 70/2005 | 367/18723 | 1.10e-06 | 2.90e-05 | 70 |
GO:001701521 | Oral cavity | NEOLP | regulation of transforming growth factor beta receptor signaling pathway | 33/2005 | 128/18723 | 1.18e-06 | 3.08e-05 | 33 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LDLRAD4 | SNV | Missense_Mutation | | c.99C>A | p.Asn33Lys | p.N33K | O15165 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.451) | TCGA-D8-A1JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
LDLRAD4 | SNV | Missense_Mutation | | c.643N>A | p.Asp215Asn | p.D215N | O15165 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
LDLRAD4 | SNV | Missense_Mutation | novel | c.161N>T | p.Pro54Leu | p.P54L | O15165 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
LDLRAD4 | SNV | Missense_Mutation | | c.791N>A | p.Gly264Asp | p.G264D | O15165 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.965) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
LDLRAD4 | SNV | Missense_Mutation | | c.665C>T | p.Ala222Val | p.A222V | O15165 | protein_coding | tolerated_low_confidence(0.06) | benign(0.021) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LDLRAD4 | SNV | Missense_Mutation | | c.493N>A | p.Glu165Lys | p.E165K | O15165 | protein_coding | tolerated(0.05) | benign(0.306) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
LDLRAD4 | SNV | Missense_Mutation | novel | c.833G>A | p.Gly278Asp | p.G278D | O15165 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LDLRAD4 | SNV | Missense_Mutation | novel | c.329N>C | p.Leu110Pro | p.L110P | O15165 | protein_coding | deleterious(0.04) | benign(0.037) | TCGA-AJ-A8CT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LDLRAD4 | SNV | Missense_Mutation | | c.619N>A | p.Ala207Thr | p.A207T | O15165 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
LDLRAD4 | SNV | Missense_Mutation | novel | c.280C>T | p.Arg94Trp | p.R94W | O15165 | protein_coding | tolerated(0.16) | benign(0.006) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |